Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

NCT06071871 is registered in ClinicalTrials.gov with University College, London as lead sponsor.

NCT NCT06071871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06071871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
Lead sponsor
University College, London
Phase
Phase 2
Overall status
Recruiting
Start date
August 16, 2024
Completion date
July 30, 2028
Enrollment
99 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

large b-cell lymphoma